Acute kidney injury (AKI), mostly defined as a rise in serum creatinine concentration (Cr) of more than 0.5 mg/dl, is a common, serious, and potentially preventable complication of percutaneous coronary intervention (PCI) and is associated with adverse outcomes including an increased risk of inhospital mortality. Recent data from the National Cardiovascular Data Registry/Cath-PCI registry (NCDR Cath-PCI Registry) 
undergoing PCI suggest that approximately 7% experienced AKI with a reported incidence of 3-19%. 1 In patients undergoing primary PCI for acute myocardial infarction (AMI), AKI occurs more frequently with rates up to 20% depending on patient and procedural characteristics. 2 However, varying definitions of AKI limit comparisons of AKI rates across different studies. Recently, most studies have adopted the Acute Kidney Injury Network (AKIN) criteria for definition and classification of AKI. 3, 4 Beyond the AKIN criteria for AKI, other classifications as the risk, injury, failure, loss and endstage kidney disease (RIFLE) 5 and kidney disease: improving global outcomes (KDIGO) criteria 6 are used to define AKI. Notably, even small increases in serum creatinine beyond AKI may be associated with adverse outcomes including increased hospital length of stay and excess costs. 2, 7 Both AKI prediction and prevention are major healthcare priorities as therapeutic options are limited when structural nephron damage occurs.
Subclinical acute kidney injury
Importantly, up to 20% of patients undergoing primary PCI for AMI who do not meet current consensus criteria for AKI may have acute tubular damage. 8 In the current issue of the journal, Margolis and colleagues 9 designed and conducted a single-centre retrospective observational study that included 1897 consecutive ST-elevation AMI patients who underwent primary PCI and had no diagnosis of AKI during the index hospitalisation. Subclinical AKI was defined as a Cr increase of more than 0.1 mg/dl and less than 0.3 mg/dl, and the association with inhospital outcomes was investigated. Outcome events included the occurrence of heart failure, atrial fibrillation, need for mechanical ventilation and inhospital mortality. Three hundred and twenty-one patients (17%) were identified to have subclinical AKI, which was associated with a two-fold increase of inhospital adverse events. In addition, further analyses revealed that the prognostic value of subclinical AKI may be independent of some patient characteristics including baseline renal function. Unfortunately, the authors missed the opportunity to strengthen the results by including stroke, re-infarction and repeated revascularisation procedures to the outcome events. In addition, information regarding medication during the course of hospitalisation, including the use of renin-angiotensin-aldosterone antagonists and diuretics was not provided. Such treatment may have influenced both Cr levels and outcome events (mediated by haemodynamic effects and cardiac remodelling).
Subclinical rise in serum creatinine: risk factor, risk marker for worse prognosis or simply innocent bystander?
Based on the study by Margolis and colleagues, 9 should risk prediction after primary PCI for AMI include subclinical rises in serum Cr and trigger changes in management strategies such as hydration regimens? For sure, the association with adverse outcomes is hypothesis generating, but it is important to consider that a causal relationship cannot be established. The extent to which unmeasured confounders contribute to the associations observed in retrospective data must always be considered carefully. 10 No prospective trials have been performed to examine whether subclinical rises in Cr have prognostic utility and should impact clinical decision-making. Indeed, several clinical characteristics, genetic and epigenetic mechanisms, and disease and procedure-related factors which have been associated with subclinical rises in serum creatinine may also in parallel fashion (but without an inter-relating mechanism) affect the outcome (i.e. epiphenomena). For example, previous reports identified age, left ventricular ejection fraction, diabetes, chronic kidney disease, occurrence of heart failure and cardiogenic shock as being independently associated with rises in Cr. 1,2 Most of these factors are also predictive of adverse outcomes including cardiovascular and all-cause mortality ( Figure 1) . 3 In addition, apart from the severity of AKI, also the cause might play an important role when considering its impact on clinical outcome. For example, structural nephron damage because of toxins or pronounced ischaemia in cardiogenic shock is much less likely to be reversible as is for instance prerenal azotaemia. As Cr poorly discriminates between AKI causes, rising Cr is not always associated with poor outcomes. Previous studies that investigated patients with heart failure have revealed that appropriate decongestion is associated with an increased risk of worsening renal function and elevated Cr but improved outcome. 11 The devil is in the detail: creatinine and other markers of kidney injury Using 24-hour urinary creatinine clearances may result in a more precise estimation of the glomerular filtration rate when compared to Cr. However, such measurements are not performed routinely in daily practice. Several equations, including the Cockcroft-Gault, the modification of diet in renal disease (MDRD), and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula are applied to calculate the glomerular filtration rate in steady-state conditions. These equations, when applied to populations, may provide reliable correlations with 24-hour creatinine clearance but have their own limitations. Moreover, the reliability of fluctuations in Cr to assess renal function is limited by the fact that beyond the true underlying glomerular filtration rate, Cr are influenced by fluid balance and fluctuations in creatinine production. 12 The role of dilution and the distribution volume of serum creatinine have to be considered when interpreting the results of the study by Margolis and colleagues 9 and haemodilution may affect Cr. Considering the fact that serum creatinine is no perfect marker of AKI, other renal biomarkers may improve the accuracy of AKI diagnosis including cystatin C, kidney injury molecule-1 (KIM-1), and neutrophil gelatinase-associated lipocalin (NGAL). 13, 14 Such biomarkers may be useful for more early detection of AKI and discriminate between causes.
Translational perspective: should we intervene?
If subclinical rises in Cr per se have a causal effect on subsequent outcome, interventions to reduce rises in Cr should improve outcomes. However, while adequate intravenous volume expansion may prevent AKI in selected patients undergoing primary PCI for AMI, 15 no large-scale trials are available to demonstrate beneficial outcomes for this intervention. 16, 17 Moreover, one may be concerned about the risk to exacerbate heart failure in this setting when volume expansion is inappropriate. The study by Margolis et al. in this issue of the journal 9 cannot offer us an answer. Importantly, the majority (approximately 80%) of patients who demonstrated a Cr rise below 0.3 mg/dL did have an uneventful inhospital course. Possible interventions (including hydration beyond usual care) based on such findings are not supported by current evidence, and may be harmful at least in selected patients. 16 
